Myriad
In Brief This Week: Roche, Myriad Genetics, Danaher, and More
News items for the in vitro diagnostics industry for the week of Sept. 13, 2021.
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
360Dx Index Maintains Steady Ascent, Increasing 3 Percent in August
Of the 29 companies in the index, 18 saw increases in their stock prices, while 11 saw declines.
Noviscend Inks Canadian Distribution Deal for Myriad Genetics Tests
The deal covers a range of Myriad's tests including risk assessment tests for breast, prostate, and other cancers.
Myriad Genetics More Than Doubles Quarterly Revenues
Although the firm is still not providing a full-year revenue estimate due to COVID-19 uncertainties, its hereditary cancer testing segment is driving strong sales growth for the firm.